Humana Inc (HUM) Position Reduced by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. reduced its position in shares of Humana Inc (NYSE:HUM) by 16.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,933 shares of the insurance provider’s stock after selling 5,162 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Humana were worth $7,164,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Nordea Investment Management AB raised its position in Humana by 17.7% in the 3rd quarter. Nordea Investment Management AB now owns 22,339 shares of the insurance provider’s stock worth $7,562,000 after purchasing an additional 3,359 shares during the last quarter. Legal & General Group Plc raised its position in Humana by 4.7% in the 3rd quarter. Legal & General Group Plc now owns 741,608 shares of the insurance provider’s stock worth $251,027,000 after purchasing an additional 33,526 shares during the last quarter. Morgan Stanley raised its position in Humana by 130.5% in the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock worth $124,712,000 after purchasing an additional 208,595 shares during the last quarter. Vanguard Group Inc raised its position in Humana by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock worth $3,420,482,000 after purchasing an additional 140,864 shares during the last quarter. Finally, Federated Investors Inc. PA raised its position in Humana by 598.6% in the 3rd quarter. Federated Investors Inc. PA now owns 134,741 shares of the insurance provider’s stock worth $45,612,000 after purchasing an additional 115,453 shares during the last quarter. Institutional investors own 94.78% of the company’s stock.

In other news, insider Christopher H. Hunter sold 15,586 shares of the business’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Roy A. Beveridge sold 8,278 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the transaction, the insider now directly owns 12,409 shares of the company’s stock, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. 0.54% of the stock is owned by insiders.

Several research firms recently weighed in on HUM. Citigroup dropped their price objective on shares of Humana from $362.00 to $302.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Oppenheimer lowered their target price on shares of Humana from $373.00 to $350.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. UBS Group began coverage on shares of Humana in a report on Tuesday, April 23rd. They set a “neutral” rating and a $266.00 target price for the company. Finally, Credit Suisse Group lowered their target price on shares of Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $337.26.

HUM opened at $243.89 on Friday. Humana Inc has a 52 week low of $225.65 and a 52 week high of $355.88. The firm has a market cap of $33.84 billion, a price-to-earnings ratio of 16.76, a price-to-earnings-growth ratio of 1.02 and a beta of 0.88. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The company had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. During the same quarter in the previous year, the business earned $3.36 EPS. The firm’s revenue was up 12.8% on a year-over-year basis. Equities analysts expect that Humana Inc will post 17.56 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is 15.12%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/humana-inc-hum-position-reduced-by-candriam-luxembourg-s-c-a.html.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: How to trade on quiet period expirations

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.